those here stating that it would be tough to approve orallyn with just one trial or with a small number of participants do not understand that GNBT is not trying to get a new drug to be approved, they are only trying to get aproval for a new delivery mechanism. without a doubt, there is an easier path for this than for a new drug.
as witnessed by the IND, FDA is on the side of Generex. I like the fact that the company does not hurry with the trials or with the NDAs, of course, as a shareholder, we want to see the stock go up sooner rather than later. but i would rather it go up and stay up than the firm to hurry and have to submit and then resubmit...
GNBT has FOUR huge things going for it:
1. THE PATENTED BUCCAL DELIVERY MECHANISM (THEY GOT A WORLDWIDE LOCKDOWN ON THIS METHOD FOR DRUG DELIVERY, ANYONE WANTING TO USE IT WILL HAVE TO PAY GENEREX)
2. cANCER VACCINES THAT ARE BEST OUT OF EVERYTHING BEING DEVELOPMENT WITH POTENTIAL FOR NOT JUST CANCER TREATMENT BUT ALSO FOR PREVENTION
3 A DIABETES DRUG THAT THE WORLD IS STARVING FOR!!!!
4. OVER THE COUNTER LINE OF PRODUCTS THAT ARE VERY PROMISING ( I BOUGHT CRAVE NX AT CVS A FEW MONTH BACK AND I LIKED IT) IT IS JUST SO EXPENSIVE ABOUT 8 BUCKS!!
You cannot forget when referring to Ecuador they are not as fortunate to have the cash resources that we do here as Americans, Ecuador is a rather poor country so most of the people would not be able to afford Oral-lyn.